Spiro-amino-imidazolone Compounds for Selective BACE Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting beta-secretase inhibition, face challenges such as undesirable side effects related to the inhibition of Cathepsin D, which can lead to retinal toxicity and other adverse effects, necessitating the development of compounds that modulate beta-secretase activity without affecting Cathepsin D pathways.
Innovation Solution
Development of a new class of compounds defined by Formula I, which include stereoisomers, tautomers, hydrates, and pharmaceutically acceptable salts, designed to regulate beta-secretase activity and reduce the formation of beta-amyloid peptide, thereby treating Alzheimer's disease and related disorders without the retinal side effects associated with Cathepsin D inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta-secretase inhibition is used to treat Alzheimer's disease, then beta-amyloid peptide formation is reduced, but retinal toxicity and other adverse effects occur due to Cathepsin D inhibition
Solution Approach 1:
The patent segments the enzyme target into two distinct entities: beta-secretase (BACE) and Cathepsin D. By designing compounds that selectively inhibit BACE while sparing Cathepsin D, the invention separates the therapeutic effect (reduced A-beta production) from the harmful effect (retinal toxicity), thereby resolving the contradiction between efficacy and safety
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular characteristics that enable selective interaction with beta-secretase. The compounds of Formula I possess particular structural features (substituents R1-R10, ring systems A1-A8) that confer selectivity for BACE over Cathepsin D, allowing the drug to exert its effect locally at the BACE enzyme without affecting Cathepsin D in retinal cells
2Reliability
If Cathepsin D inhibition occurs alongside beta-secretase inhibition, then beta-amyloid formation is reduced, but retinal toxicity and other adverse effects are caused
Solution Approach 1:
The invention extracts the harmful dual-inhibition mechanism from the therapeutic approach. By removing Cathepsin D inhibition from the compound's mechanism of action and retaining only beta-secretase inhibition, the patent eliminates the source of retinal toxicity while preserving the therapeutic benefit of reduced beta-amyloid formation
Solution Approach 2:
The patent introduces selective binding as an intermediary mechanism between the compound and the enzyme targets. The compounds of Formula I act as selective mediators that preferentially bind to beta-secretase with high affinity while having minimal interaction with Cathepsin D, thereby mediating the therapeutic effect without triggering the harmful pathway
Data Source
AI summary
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:wherein variables A1, A3, A4, A5, A6, A8, L, R2, R7, R9, W and Y of Formula I are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to plaque formation and deposition, resulting from the activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, sub-Formula embodiments of Formulas I, II and III, intermediates and processes and methods useful for the preparation of compounds of Formulae I-III.